trending Market Intelligence /marketintelligence/en/news-insights/trending/lTGPwaPGa8kmnAqRXL2XUw2 content esgSubNav
In This List

Sanofi sues Merck & Co. unit over patents for insulin drug

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Commercial Banking Newsletter June Edition - 2022

Blog

Insight Weekly: US recession outlook; mortgage activity slowdown; climate disclosure push


Sanofi sues Merck & Co. unit over patents for insulin drug

Sanofi sued Merck Sharp & Dohme Corp. alleging that the Merck & Co. Inc. unit infringed on two patents for its insulin product Lantus.

The suit, filed in the U.S. District Court for the District of New Jersey, was triggered by notification from Merck in June that it had filed a new drug application with the U.S. Food and Drug Administration for an insulin glargine vial drug product.

Merck's application included a certification challenging all Sanofi patents listed in the FDA orange book for Lantus and Lantus SoloStar products.